Ouch, been a rough year for mml. What's with the non asx-200 goldies doing relatively well but the non asx-200 goldies performing poorly?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025